H. Amy Xia - Search Results

Year	Number of Results
2006	2
2007	2
2008	1
2009	1
2011	3
2012	2
2013	5
2014	3
2015	1
2017	1
2020	2
2021	1
2022	2
2023	1
2024	0

1

Landmark mediation survival analysis using longitudinal surrogate.

Zhou J, Jiang X, Xia HA, Hobbs BP, Wei P. Zhou J, et al. Among authors: xia ha. Front Oncol. 2023 Jan 17;12:999324. doi: 10.3389/fonc.2022.999324. eCollection 2022. Front Oncol. 2023. PMID: 36733365 Free PMC article.

2

Safety monitoring in clinical trials.

Yao B, Zhu L, Jiang Q, Xia HA. Yao B, et al. Among authors: xia ha. Pharmaceutics. 2013 Jan 17;5(1):94-106. doi: 10.3390/pharmaceutics5010094. Pharmaceutics. 2013. PMID: 24300399 Free PMC article.

3

Predicting outcomes of phase III oncology trials with Bayesian mediation modeling of tumor response.

Zhou J, Jiang X, Xia HA, Wei P, Hobbs BP. Zhou J, et al. Stat Med. 2022 Feb 20;41(4):751-768. doi: 10.1002/sim.9268. Epub 2021 Dec 9. Stat Med. 2022. PMID: 34888892

4

Bayesian adaptive design for concurrent trials involving biologically related diseases.

Psioda MA, Xia HA, Jiang X, Xu J, Ibrahim JG. Psioda MA, et al. Among authors: xia ha. Biostatistics. 2020 Apr 8:kxab008. doi: 10.1093/biostatistics/kxab008. Online ahead of print. Biostatistics. 2020. PMID: 33982753

5

Pharmacokinetic/pharmacodynamic data extrapolation models for improved pediatric efficacy and toxicity estimation, with application to secondary hyperparathyroidism.

Basu C, Ma X, Mo M, Xia HA, Brundage R, Al-Kofahi M, Carlin BP. Basu C, et al. Pharm Stat. 2020 Nov;19(6):882-896. doi: 10.1002/pst.2043. Epub 2020 Jul 9. Pharm Stat. 2020. PMID: 32648333

6

Bayesian methods for design and analysis of safety trials.

Price KL, Xia HA, Lakshminarayanan M, Madigan D, Manner D, Scott J, Stamey JD, Thompson L. Price KL, et al. Among authors: xia ha. Pharm Stat. 2014 Jan-Feb;13(1):13-24. doi: 10.1002/pst.1586. Epub 2013 Jul 30. Pharm Stat. 2014. PMID: 23897858

7

Statistical Evaluation of Drug Safety Data.

Xia HA, Jiang Q. Xia HA, et al. Ther Innov Regul Sci. 2014 Jan;48(1):109-120. doi: 10.1177/2168479013510917. Ther Innov Regul Sci. 2014. PMID: 30231415

8

The FDA's Final Rule on Expedited Safety Reporting: Statistical Considerations.

Wittes J, Crowe B, Chuang-Stein C, Guettner A, Hall D, Jiang Q, Odenheimer D, Xia HA, Kramer J. Wittes J, et al. Among authors: xia ha. Stat Biopharm Res. 2015 Jul 3;7(3):174-190. doi: 10.1080/19466315.2015.1043395. Epub 2015 Oct 9. Stat Biopharm Res. 2015. PMID: 26550466 Free PMC article.

9

Statistical modeling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation.

Gamalo-Siebers M, Savic J, Basu C, Zhao X, Gopalakrishnan M, Gao A, Song G, Baygani S, Thompson L, Xia HA, Price K, Tiwari R, Carlin BP. Gamalo-Siebers M, et al. Among authors: xia ha. Pharm Stat. 2017 Jul;16(4):232-249. doi: 10.1002/pst.1807. Epub 2017 Apr 27. Pharm Stat. 2017. PMID: 28448684

10

Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment.

Gelfand JM, Kimball AB, Mostow EN, Chiou CF, Patel V, Xia HA, Freundlich B, Stevens SR. Gelfand JM, et al. Among authors: xia ha. Value Health. 2008 May-Jun;11(3):400-7. doi: 10.1111/j.1524-4733.2007.00251.x. Value Health. 2008. PMID: 18489665 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

20 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year